Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chukwuma Onyewu

Interventional Pain Medicine Lanham, MD Medical Doctor

NPI 1578573457 CMS profile 948912

9841 Greenbelt Rd Ste 208, Lanham, MD 20706

Open in the dashboard

General payments

$7,817

391 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chukwuma Onyewu of Lanham, MD is reported in the CMS Open Payments database as having received $7,817 across 391 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,428 61
2024 General $994 44
2023 General $1,117 56
2022 General $1,591 69
2021 General $931 47
2020 General $412 30
2019 General $1,343 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chukwuma Onyewu
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Chukwuma Onyewu were reported at $1,428. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Chukwuma Onyewu Interventional Pain Medicine median Middle half National median
2019 $1,343 $684 $216–$2,079 $163
2020 $412 $382 $122–$1,109 $114
2021 $931 $552 $167–$1,554 $132
2022 $1,591 $605 $187–$1,924 $149
2023 $1,117 $671 $195–$1,915 $160
2024 $994 $684 $206–$1,837 $164
2025 $1,428 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,335 104 payments
  2. Medtronic, Inc. $880 16 payments
  3. AbbVie, Inc. $800 38 payments
  4. Collegium Pharmaceutical, Inc. $789 44 payments
  5. Abbott Laboratories $537 20 payments
  6. Boston Scientific Corporation $362 13 payments
  7. Scilex Pharmaceuticals Inc. $339 18 payments
  8. Curonix LLC $240 2 payments
  9. Orexo US, Inc. $221 9 payments
  10. Pfizer Inc. $208 11 payments
  11. Other $2,106 116 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,726 379 payments
  2. Education $91 12 payments
Products named General payments · program years 2019–2025
  1. RELISTOR Gastroenterology $1,098 89 payments
  2. RELISTOR Gastroenterology $935 79 payments
  3. UBRELVY $648 31 payments
  4. XTAMPZA $507 28 payments
  5. BELBUCA $282 16 payments
  6. ZTLido $269 14 payments
  7. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $240 2 payments
  8. INTELLIS $223 3 payments
  9. Zubsolv $221 9 payments
  10. QULIPTA $176 8 payments
  11. Other $4,266 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

5,629

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$463,586

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

27.9%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 47 $130,013
Belbuca Buprenorphine Hcl Brand 61 $48,963
Xtampza Er Oxycodone Myristate Brand 85 $43,008
Oxycontin Oxycodone Hcl Brand 66 $24,828
Nucynta Tapentadol Hcl Brand 13 $23,544
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 607 $17,394
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 59 $17,220
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 12 $14,780
Ztlido Lidocaine Brand 29 $14,165
Lidocaine Generic 134 $13,532

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$127,881

Of which drugs: $4,230

Medicare patients

375

Average age 65

Services billed

2,106

253 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 43%
Depression 38%
Ischemic heart disease 26%
Chronic kidney disease 25%
COPD 23%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $123
$123 61 —
ZTLido
  • Scilex Pharmaceuticals Inc. $104
$104 29 —
UBRELVY
  • AbbVie, Inc. $76
$76 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $74
$74 47 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $63
$63 85 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

391 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record